United States pharmaceutical maker, Pfizer, and biopharmaceutical company, Global Blood Therapeutics (GBT), on Monday, agreed that Pfizer would acquire GBT in an all-cash deal valued at 5.4 billion U.S. dollars.
Pfizer said the acquisition would drive growth by enhancing its work in rare hematology while reinforcing the company’s commitment to sickle cell disease research and treatment.
According to dpa, under the terms of the transaction, Pfizer will acquire all the outstanding shares of California-based GBT for 68.50 dollars per share in cash, for a total enterprise value of approximately 5.4 billion dollars, including debt and net of cash acquired.
READ ALSO: BioNTech, Pfizer to develop vaccine against shingles
The pharmaceutical company expects to finance the transaction with existing cash on hand.
The proposed transaction, unanimously approved by the Boards of Directors of both companies, is subject to customary closing conditions, including receipt of regulatory approvals and approval by GBT’s stockholders.
A Nigerian pharmacist and doctoral researcher at McGill University, Chika Onochie, has received a research…
Troops of the Nigerian Army have rescued some prospective National Youth Service Corps members abducted…
Bandits have killed a resident and abducted nine persons, including his wife and two children,…
A 42-year-old patient has died in India after the ambulance conveying him was stopped by…
Several travellers have reportedly been abducted after suspected bandits intercepted two commercial buses along the…
The governorship candidate of the All Progressives Congress in Ogun State, Senator Solomon Olamilekan Adeola,…
This website uses cookies.